These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 17907167)

  • 41. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
    Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
    J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP
    Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study.
    Mandl P; Balint PV; Brault Y; Backhaus M; D'Agostino MA; Grassi W; van der Heijde D; de Miguel E; Wakefield RJ; Logeart I; Dougados M
    Arthritis Care Res (Hoboken); 2013 Jun; 65(6):879-87. PubMed ID: 23213004
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.
    Wakabayashi H; Hasegawa M; Nishioka Y; Minami Y; Nishioka K; Sudo A
    Clin Rheumatol; 2013 Feb; 32(2):253-9. PubMed ID: 23179002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
    Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens].
    Cuomo G; Molinaro G; La Montagna G; Migliaresi S; Valentini G
    Reumatismo; 2006; 58(1):22-5. PubMed ID: 16639484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
    Mack ME; Hsia E; Aletaha D
    Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
    Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
    J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.